后发性白内障基因治疗的研究进展  

The research progress of gene therapy in posterior capsule opacification

作　　者：董敏[1] 康刚劲[1] 

机构地区：[1]泸州医学院附属医院眼科,四川省泸州市646000

出　　处：《眼科新进展》2013年第10期997-1000,共4页Recent Advances in Ophthalmology

摘　　要：后发性白内障是白内障术后最常见的并发症,亦是白内障患者术后视力下降的主要原因。目前尚无安全的药物治疗方法,Nd:YAG激光虽然有效,但存在一定的并发症。随着分子生物学的不断发展,基因治疗为后发性白内障的防治开辟了一条新途径。本文对后发性白内障自杀基因和基因干扰治疗的研究进展作一综述。Posterior capsule opacification （PCO） is the most common post-opera- tive complication for cataract surgery, and it is also the main cause for decreased vision of cataract patients after operation. At present,there is no safe drug treatment for PCO, although Nd：YAG laser is effective, there are some complications. With the development of molecular biology, the prevention and treatment of PCO by gene therapy opened up a new way. This paper gives a review of the research progress specific to the suicide gene therao_v and ~ene interference treatment of PCO.

关 键 词：后发性白内障 自杀基因 基因治疗 BAX基因 反义c—myc基因 RNAi 

分 类 号：R776.1[医药卫生—眼科]